Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1139 in Moderate to Severe Plaque Psoriasis
NCT07719530Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1139 in plaque psoriasis, sponsored by Hengrui Therapeutics. Started Aug 2026; status: recruiting.
02
Drugs
SHR-1139
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07719530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719530.